Drug
Blu 263
Blu 263: highest development phase Phase 1, developed by Blueprint Medicines. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Blueprint Medicines
Trials
| Drug | Phase | Indication |
|---|---|---|
| BLU-263 NCT05609942 | Phase 1 | Advanced Systemic Mastocytosis |
Latest
No recent events.
Follow Blu 263 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.